Inclusion Criteria:  Meet hemophagocytic lymphohistiocytosis (HLH)-04 diagnostic criteria; EBV-DNA in peripheral blood or EBER in tissue were positive, patients were diagnosed with EBV associated HLH (EBV-HLH). No HLH induction therapy was performed. The expected survival time is more than 1 month. Age >18 years old, gender is not limited. Serum creatinine ≤ 1.5 times normal； Serum human immunodeficiency virus(HIV) antigen or antibody negative； Hepatitis C virus (HCV) antibody is negative, or HCV antibody is positive, but HCV RNA is negative；HBV copies less than 1E+03 copies/ml. No thyroid dysfunction. The left ventricular ejection fraction (LVEF) was normal. No uncontrollable infection. Contraception for both male or female. Informed consent obtained.  Exclusion Criteria:  Allergic to doxorubicin, etoposide and sintilimab Injection Serious immunoreaction: myocardial damage, hepatitis, pneumonia Central nervous system symptoms Serious mental illness; Central nervous system symptoms Serious mental illness; Accumulated dose of doxorubicin above 300mg/m2 or epirubicin above 450mg/m2； Pancreatitis history. Patients unable to comply during the trial and/or follow-up phase; Participate in other clinical research at the same time.